IN THE UNITED STATES PATENT AND TRADEMARK OF

Confirmation No.: 6687

1614

Art Unit:

Examiner: Weddington,

Atty. Docket: 0609.4550001/JAG/FRC

In re application of:

BUSH et al.

Appl. No. 09/956,980

Filed: September 21, 2001

For:

Agents for Use in the Treatment of

Alzheimer's Disease

Amendment And Reply Under 37 C.F.R. § 1.111

Commissioner for Patents Washington, D.C. 20231

Sir:

In reply to the Office Action dated June 19, 2002, (PTO Prosecution File Wrapper Paper No. 10), the period for reply having been extended three (3) months by petition and payment of the appropriate fee, Applicants submit the following Amendment and Remarks. This Amendment is provided in the following format:

- (A) A clean version of each replacement paragraph/section/claim along with clear instructions for entry;
- (B) Starting on a separate page, appropriate remarks and arguments. 37 C.F.R. § 1.121 and MPEP 714; and
- (C) Starting on a separate page, a marked-up version entitled: "Version with markings to show changes made."

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

Amendments

In the Specification:

At page 1, immediately after the title, please replace the paragraph and caption that were inserted into the specification (*See* Preliminary Amendment filed September 21, 2001) with the following:

CROSS-REFERENCE TO RELATED APPLICATIONS

BI

The present application is a divisional application of U.S. Patent Application No. 09/038,154, filed March 11, 1998, now U.S. Patent No. 6,323,218, issued November 27, 2001.

In the Claims:

Please cancel claims 13-15, 28-30, 43-45 and 55-57 without prejudice or disclaimer.

Please substitute the following claim 12 for the pending claim 12:

12. (Once amended) The method of claim 11, wherein the chelator is bathocuproine.